The suit has been filed in the U.S. District Court for the District of Columbia against Cephalon. According to the Commission, Cephalon, faced with threat to its Provigil monopoly, paid more than $200 million to generic drug companies to abandon their patent challenges and forgo entry into the market until April 2012. As Cephalon's CEO allegedly put it shortly after entering these settlements: "We were able to get six more years of patent protection. That's $4 billion in sales no one expected".
The FTC is clearly taking the issue very seriously, see also here.
-
The DSA delivers, the DSA delivers not Sitting in a city park, looking at an impressive number of daisies, I am finally listening to the ver...
-
P. Girnus, here. I am the Executive Director of an independent AI policy think tank. Independent means we don't take government money....
-
What is particularly encouraging is that he's not someone who has lived exclusively within the competition policy world/bubble, but rath... -
L. Hof, here.
-
Politico.eu, here. On the one hand, one has Caffarra, and others like her, insisting that the whole thing is a farce. On the other, there ...
-
OECD, here. Tbd today, Trento U.
-
M. Peitz, here . [Disagree, of course]
-
Elementary, Meta, here .
No comments:
Post a Comment